Related Experiment Video
Updated: Aug 20, 2026
Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
Published on: August 9, 2019
[Effect of IL-15 on the proliferation and differentiation of CD34+ cells from MDS patients]
Zhong-Lu Ye1, Ming-Zhen Chen, Ri-Ling Chen
1Deparement of Pediatrics, Affiliated Hospital of Guangdong Medical College, Zhanjiang 524001, China. lzy8151@sohu.com
Aim:
To explore the effect of IL-15 on proliferation and differentiation of CD34 (+) cells from MDS patients.
Methods:
The CD34 (+) cells were separated by magnetic bead-activated cell sorter (MACS) system, and cultured in fluid or methylcellulose semisolid medium. MTT colorimetry was used to examine the inhibitory effect of IL-15 on the proliferation of MDS CD34(+) cells.The numbers of CD34(+)cells and colony formation of CFU-E, BFU-E, CFU-G, CFU-GEMM were counted. The expressions of CD33, CD13, CD71, CD19 and CD3 on cultured cells and the change of cell-cycle were analyzed by FCM.
Results:
The recovery rate of CD34(+) cells was (75.4+/-5.2) %, the purity of CD34 (+) cells in positive fraction was (90.3+/-6.3) % and the enriched rate was (83.1+/-12.5) % in 11 MDS patients. MTT colorimetry detection showed that IL-15 could promote the proliferation of MDS CD34(+) cells. The optimal time of promotoing CD34(+) cell proliferation by IL-15 was 8 days and optimal dosage of IL-15 was 20 microg/L. After culture for 8 days with 0 microg/L IL-15 (control group) and 20 microg/L IL-15(experimental group), the number of CD34 (+) cells increased by 4.6-fold in control group and 6.3-fold in experimental group (P<0.05, n=5). The colony formation rates of experimental group were significantly higher than those of control group. The expression rates of the CD molecules (except for CD3) on CD34(+) in experimental group were notably higher than those in control group. As compared with control group, much more CD34(+) cells of experimental group were in G(2) and S phase of cell cycle(P<0.05, n=7).
Conclusion:
IL-15 can obviously promote the proliferation and differentiation of CD34(+) cells from MDS patients.
Insights
Interleukin-15 (IL-15) significantly enhances the proliferation and differentiation of CD34(+) cells in patients with myelodysplastic syndromes (MDS). This finding suggests IL-15 as a potential therapeutic agent for MDS by promoting the growth of these crucial blood-forming cells.
Area of Science:
- Hematology
- Immunology
- Cell Biology
Context:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- CD34(+) cells are crucial hematopoietic stem and progenitor cells.
- The role of cytokines like Interleukin-15 (IL-15) in MDS pathogenesis requires further elucidation.
Purpose:
- To investigate the impact of IL-15 on the proliferation and differentiation of CD34(+) cells isolated from MDS patients.
- To determine the optimal conditions for IL-15's effect on MDS-derived CD34(+) cells.
Summary:
- Magnetic bead-activated cell sorting isolated CD34(+) cells from MDS patients.
- MTT assays and cell counting demonstrated that IL-15 (optimal dose 20 microg/L at 8 days) significantly promoted CD34(+) cell proliferation.
- IL-15 treatment increased colony formation, upregulated CD molecule expression (CD33, CD13, CD71), and promoted cell cycle progression (G2/S phases) in MDS CD34(+) cells.
Impact:
- IL-15 demonstrates a clear ability to enhance the proliferation and differentiation of CD34(+) cells in MDS.
- These findings highlight IL-15 as a potential therapeutic candidate for stimulating hematopoiesis in MDS.
- Further research may explore IL-15's clinical utility in managing MDS-related cytopenias.
